The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
IFN treatment has disease modification potential. What percentage of patients treated with pegylated IFNα-2 experienced an absolute change in JAK2V617F allele burden from baseline to month 60?
A
B
C
D
Hydroxyurea (HU) is the most commonly used cytoreductive therapy in patients diagnosed with myeloproliferative neoplasms (MPN); however, treatment presents leukemogenic potential. Pegylated interferon alfa-2 (pegIFNα-2) offers an alternative therapeutic approach, with high response rates and disease modification potential. Each treatment presents its advantages and disadvantages; therefore, the phase III DALIAH trial (NCT01387763) was conducted to compare low-dose pegIFNα-2 with HU in patients diagnosed with MPN.
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Knudsen presented a final analysis of the phase III DALIAH trial. We summarize the key results below.
Check out our top abstracts, presented at the 65th ASH Annual Meeting and Exposition, here. For more information on the DALIAH trial and the quality of life outcomes experienced by patients who were enrolled, read our previous MPN Hub article.
The baseline patient characteristics are shown in Table 1.
Table 1. Baseline patient characteristics*
ET, essential thrombocythemia; HU, hydroxyurea; IFN, interferon; pegIFN, pegylated interferon; PMF, primary myelofibrosis; PV, polycythemia vera. |
||||
Characteristic,% (unless otherwise specified) |
HU |
IFN combined |
Total |
p value |
---|---|---|---|---|
Median age, years |
68 |
59 |
62 |
<0.0001 |
Male |
63 |
54 |
56 |
0.37 |
MPN diagnosis |
||||
ET |
39 |
24 |
36 |
0.09 |
PV |
41 |
55 |
44 |
0.15 |
Pre-PMF |
9 |
3 |
8 |
0.32 |
PMF |
11 |
18 |
12 |
0.27 |
IFN treatment type |
||||
pegIFNα-2a |
— |
50 |
50 |
— |
pegIFNα-2b |
— |
50 |
50 |
— |
JAK2V617F allele burden |
37 |
33 |
34 |
0.78 |
Figure 1. Patients who remained on treatment and experienced a molecular response with either HU or pegIFNα-2*
HU, hydroxyurea; IFN, interferon; pegIFNα-2, pegylated interferon alfa-2.
*Adapted from Knudsen.1
Figure 2. Patients who remained on treatment and experienced a complete hematologic response with either HU or pegIFNα-2*
HU, hydroxyurea; IFN, interferon; pegIFNα-2, pegylated interferon alfa-2.
*Adapted from Knudsen.1
The percentage of patients who experienced no change or improvement in bone marrow fibrosis grading was similar with both pegIFNα-2 and HU treatment; however, a higher percentage of patients treated with pegIFNα-2 experienced a worsening of fibrosis (Figure 3).
Figure 3. Patients who experienced a change in bone marrow fibrosis grade, treated with pegIFNα-2 or HU*
HU, hydroxyurea; IFN, interferon; pegIFNα-2, pegylated interferon alfa-2.
*Adapted from Knudsen.1
This final analysis of the DALIAH trial showed no difference in molecular or complete hematologic response between pegIFNα-2 and HU. However, there was a greater reduction in JAK2V617F allele burden with pegIFNα-2 treatment at 36 months and beyond compared with HU. Treatment discontinuation was higher with pegIFNα-2 treatment, despite a low-dose approach. Patients with good tolerability to pegIFNα-2 therapy experienced superior efficacy beyond 36 months compared with HU.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content